[Monocrotaline induce pulmonary hypertension in animal models].
The pulmonary hypertension is a serious disease, difficult to treat, and its mechanisms remain however to be elucidated. It is known that administration of small doses of MCT or its active metabolite, monocrotaline pyrrole (MCTP); to rats causes delayed and progressive lung injury characterized by pulmonary vascular remodeling which induces pulmonary hypertension. The purpose of this article is to get used to vascular, cellular and molecular changes in pulmonary hypertension, in order to create a personal experimental animal model. This experimental model will try to find new ways of therapeutical strategies in human pulmonary hypertension.
Alexandru
B
B
Clinica de Pneumologie, U.M.F. Carol Davila.
Bogdan
M A
MA
D000818:Animals; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects*; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000503:physiopathology; D017380:Hypertrophy, Right Ventricular / Q000139:chemically induced; D016686:Monocrotaline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar
C014114:monocrotaline pyrrole; D016686:Monocrotaline